Professor Raymond G. Hill, BPharm PhD DSc (Hon) FMedSci.

Until 30th April 2008, Professor Hill was Executive Director, Licensing and External Research, Europe for Merck, Sharp and Dohme Research Laboratories, a subsidiary of Merck & Co., Inc. Dr. Hill has worked in the pharmaceutical industry for over 25 years initially for Parke Davis then Smith Kline and French and, more recently (1990 - 2008 ), for Merck. As Executive Director, Pharmacology at the Neuroscience Research Centre at Merck, Ray chaired the Merck Analgesia Task Force, coordinating basic research worldwide and between 1997 and 2002 he had oversight responsibility for Neuroscience research at the Banyu Research Labs in Tsukuba, Japan. At Merck he chaired discovery project teams responsible for the marketed products Maxalt® and Emend®.

Dr. Hill is also currently a non-executive director of Addex Pharmaceuticals and of Orexo AB, Visiting Professor in Neuroscience and Mental Health, Imperial College London, Visiting Industrial Professor of Pharmacology in the University of Bristol, Visiting Professor and Chairman of the External Advisory Board in the School of Biological and Health Sciences at the University of Surrey and Visiting Professor in Physiology and Pharmacology at the University of Strathclyde. He is a Director and Trustee of the Babraham Institute, Cambridge. Dr Hill received BPharm and PhD degrees from the University of London and was elected to Fellowship of the Academy of Medical Sciences in 2005. He was a lecturer in Pharmacology at the University of Bristol School of Medicine from 1974 to 1983. He is President-Elect and Chair of the Executive Committee of the British Pharmacological Society and a member of the Nuffield Council on Bioethics.